A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Sandrine J. Faivre, Armando Santoro, Robin Kate Kelley, Philippe Merle, Ed Gane, Jean-Yves Douillard, Dirk Waldschmidt, Mary Frances Mulcahy, Charlotte Costentin, Beatriz Minguez, Pasqua Papappicco, Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Michael M. Lahn, Sophie Ameryckx, Karim A. Benhadji, Eric Raymond, Gianluigi Giannelli
Institutions: Hôpital Beaujon, UCSF Helen Diller Family Comprehensive Cancer Center, Hôpital de la Croix-Rousse, Auckland City Hospital, University Hospital Cologne, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Hôpitaux Universitaires Henri-Mondor, Vall d'Hebron Hospital Universitari, University of Bari Aldo Moro, Eli Lilly (United States)
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2197145779
